Chris Viehbacher, Biogen CEO (Suzanne Kreiter/The Boston Globe via Getty Images)
Will slow uptake of Leqembi pose a risk to Biogen’s recovery?
If Biogen’s dismal stock performance on Tuesday is any indication, Leqembi could be the single biggest factor in the company’s ability to right the ship …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.